Serotonin 1D (5-HT1D) agonists and other agents in acute migraine (Q41371800)

30 September 2017

1 reference

title

Serotonin 1D (5-HT1D) agonists and other agents in acute migraine (English)

1 reference

30 September 2017

Mathew NT

1

1 reference

30 September 2017

publication date

1 February 1997

1 reference

30 September 2017

1 reference

30 September 2017

volume

15

1 reference

30 September 2017

issue

1

1 reference

30 September 2017

page(s)

61-83

1 reference

30 September 2017

cites work

Sumatriptan and migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan in the Treatment of Acute Migraine With Aura

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Endogenous pain control mechanisms: Review and hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

1 reference

7 January 2021

Subcutaneous sumatriptan during the migraine aura

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

The safety of concomitant use of sumatriptan and antidepressant treatments

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan-induced chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

The safety and tolerability of sumatriptan: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Efficacy of subcutaneous sumatriptan in repeated episodes of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Oral sumatriptan in the treatment of recurrent headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Treatment of Acute Migraine With Subcutaneous Sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

A controlled study of dihydroergotamine in the treatment of acute migraine headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Coronary vasospasm and sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Ergotamine-induced headache can be sustained by sumatriptan daily intake.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan-induced stroke in sagittal sinus thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Twin studies in medical research

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Cardiorespiratory distress after sumatriptan given by injection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Clinical experiences from Sweden on the use of subcutaneously administered sumatriptan in migraine and cluster headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Emergency management of headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Cluster headache attacks treated for up to three months with subcutaneous sumatriptan (6 mg). Sumatriptan Cluster Headache Long-term Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. The Sumatriptan Cluster Headache Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan in chronic cluster headache: results of continuous treatment for eleven months

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

The efficacy and safety of subcutaneous sumatriptan in the acute treatment of menstrual migraine. The Sumatriptan Menstrual Migraine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Rationale for the use of 5-HT1-like agonists in the treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Clinical and experimental effects of sumatriptan in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Clinical effects and mechanism of action of sumatriptan in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

The Clinical Pharmacology, Pharmacokinetics and Metabolism of Sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Misuse of sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

1 reference

7 January 2021

Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Oral sumatriptan in acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Human in vivo evidence for trigeminovascular activation in cluster headache. Neuropeptide changes and effects of acute attacks therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan in cluster headache: a time study of the effect on pain and autonomic symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan and chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan and chest pain

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Cardiorespiratory distress after sumatriptan given by injection

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Parenteral chlorpromazine treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Randomized double-blind trial of intravenous prochlorperazine for the treatment of acute headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

1 reference

7 January 2021

Cardiac arrest following use of sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Rapid and sustained relief of migraine attacks with intranasal lidocaine: preliminary findings

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Intravenous chlorpromazine--preliminary results in acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Long term use of sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

The safety of sumatriptan in asthmatic migraineurs

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Adverse reactions associated with sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Drug induced refractory headache--clinical features and management

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Serotonin syndrome complicating migraine pharmacotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Preemptive oral treatment with sumatriptan during a cluster period

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Vasospasm-induced myocardial infarction with sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Life-threatening ventricular arrhythmias in patients with silent myocardial ischemia due to coronary-artery spasm

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Oral sumatriptan compared with placebo in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Is there a problem with long-term use of sumatriptan in migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Comorbidity of migraine and epilepsy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Transmural myocardial infarction with sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Does chronic use of sumatriptan induce dependence?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Oral sumatriptan in preventing headache recurrence after treatment of migraine attacks with subcutaneous sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Repetitive intravenous dihydroergotamine as therapy for intractable migraine.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device: comparison with customary treatment in an open, longitudinal study.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Lack of an interaction between propranolol and sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Subcutaneous sumatriptan in a clinical setting: the first 100 consecutive patients with acute migraine in a tertiary care center

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Repetitive intravenous DHE in the treatment of refractory headache

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan: a clinical standard?

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Coronary vasospasm and sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan-induced [correction of Sumatripan] stroke in sagittal sinus thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan in the acute treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Long-term experience with sumatriptan in the treatment of migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

A placebo-controlled study of intranasal sumatriptan for the acute treatment of migraine. The Finnish Sumatriptan Group and the Cardiovascular Clinical Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. The Multinational Oral Sumatriptan and Cafergot Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. The Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan--an oral dose-defining study. The Oral Sumatriptan Dose-Defining Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. The Oral Sumatriptan International Multiple-Dose Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Self-treatment of acute migraine with subcutaneous sumatriptan using an auto-injector device. The Sumatriptan Auto-Injector Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Treatment of Acute Cluster Headache with Sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan-nonresponders: a survey in 366 migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Sumatriptan in clinical practice: a 2-year review of 453 migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Migraine and cluster headache--their management with sumatriptan: a critical review of the current clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Coronary vasospasm induced by subcutaneous sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Paroxetine treatment and the prolactin response to sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

Office-based treatment of acute migraine with dihydroergotamine mesylate

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8619%2805%2970295-4

7 January 2021

10.1016/S0733-8619(05)70295-4

Identifiers

DOI

1 reference

30 September 2017

1 reference